Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 1/20 | 0.55 |
| ▸ | DHPS | P49366 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262953 | 0.90 | WHR1 (0.54) | WHR1DHPSKDM4ESTAT6NPSR1 | |
| SCHEMBL16384708 | 0.88 | WHR1 (0.52) | WHR1DHPSKDM4ESTAT6NPSR1 | |
| SCHEMBL3976324 | 0.88 | SLC2A1 (0.56) | WHR1DHPSKDM4ESTAT6NPSR1 | |
| SCHEMBL10063506 | 0.88 | WHR1 (0.52) | WHR1DHPSKDM4ESTAT6NPSR1 | |
| SCHEMBL20771102 | 0.88 | WHR1 (0.71) | WHR1DHPSKDM4ESTAT6NPSR1 | |
| SCHEMBL29589069 | 0.88 | WHR1 (0.71) | WHR1DHPSKDM4ESTAT6NPSR1 | |
| SCHEMBL3469022 | 0.87 | WHR1 (0.54) | WHR1KDM4ESTAT6NPSR1KMT2A | |
| SCHEMBL29589358 | 0.87 | WHR1 (0.54) | WHR1KDM4ESTAT6NPSR1KMT2A | |
| SCHEMBL5258730 | 0.85 | WHR1 (0.52) | WHR1KDM4ESTAT6NPSR1KMT2A | |
| SCHEMBL5261050 | 0.85 | WHR1 (0.49) | WHR1KDM4ESTAT6NPSR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640392-B1 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-01-07 | — | — | EP | disclosed |
| US-8815879-B2 | Substituted 4-(selenophen-2(or-3)-ylamino)pyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815879-B2 | Substituted 4-(selenophen-2(or-3)-ylamino)pyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-10 | — | — | US | disclosed |
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-10 | — | — | US | disclosed |
| EP-2640392-A2 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-09-25 | — | — | EP | disclosed |
| CN-103221048-A | Substituted 4- (selenophen-2 (or 3) -ylamino) pyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD | 2013-07-24 | — | — | CN | disclosed |
| WO-2012066578-A2 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-05-24 | — | — | WO | disclosed |
| EP-1040101-B1 | SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-04-25 | — | — | EP | disclosed |
| US-6613772-B1 | Drugs such as 2-(p-chlorophenyl-4-(4-hydroxybutyl)amino-6,7,8 -trimethoxyquinazoline used for activation of guanylate cyclase and modulation of cyclic guanosine monophosphate | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-02 | — | — | US | disclosed |
| EP-1040101-A1 | SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032460-A1 | SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266563-A1 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | RPS6, SULT1E1, SCLY | WHR1 1848/4885DHPS 980/4885KDM4E 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.